Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report

The aim of the present study was to report a rare case of head and neck adenocarcinoma with an unknown primary site in a 59-year-old man. After disease progression followed by multiple cycles of chemotherapy and radiotherapy, genetic screening using next-generation sequencing identified vascular end...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jingxian, Cheng, Chien-shan, Chen, Jie, Lv, Lingling, Shen, Xiaoheng, Zheng, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683926/
https://www.ncbi.nlm.nih.gov/pubmed/33203264
http://dx.doi.org/10.1177/0300060520964355
_version_ 1783612981186134016
author Chen, Jingxian
Cheng, Chien-shan
Chen, Jie
Lv, Lingling
Shen, Xiaoheng
Zheng, Lan
author_facet Chen, Jingxian
Cheng, Chien-shan
Chen, Jie
Lv, Lingling
Shen, Xiaoheng
Zheng, Lan
author_sort Chen, Jingxian
collection PubMed
description The aim of the present study was to report a rare case of head and neck adenocarcinoma with an unknown primary site in a 59-year-old man. After disease progression followed by multiple cycles of chemotherapy and radiotherapy, genetic screening using next-generation sequencing identified vascular endothelial growth factor A amplification and the TP53 R209Kfs mutation. Treatment with the multi-targeted protein kinase inhibitor sorafenib controlled the patient’s symptoms and improved his quality of life.
format Online
Article
Text
id pubmed-7683926
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-76839262020-12-03 Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report Chen, Jingxian Cheng, Chien-shan Chen, Jie Lv, Lingling Shen, Xiaoheng Zheng, Lan J Int Med Res Case Report The aim of the present study was to report a rare case of head and neck adenocarcinoma with an unknown primary site in a 59-year-old man. After disease progression followed by multiple cycles of chemotherapy and radiotherapy, genetic screening using next-generation sequencing identified vascular endothelial growth factor A amplification and the TP53 R209Kfs mutation. Treatment with the multi-targeted protein kinase inhibitor sorafenib controlled the patient’s symptoms and improved his quality of life. SAGE Publications 2020-11-17 /pmc/articles/PMC7683926/ /pubmed/33203264 http://dx.doi.org/10.1177/0300060520964355 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Chen, Jingxian
Cheng, Chien-shan
Chen, Jie
Lv, Lingling
Shen, Xiaoheng
Zheng, Lan
Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report
title Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report
title_full Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report
title_fullStr Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report
title_full_unstemmed Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report
title_short Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report
title_sort sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683926/
https://www.ncbi.nlm.nih.gov/pubmed/33203264
http://dx.doi.org/10.1177/0300060520964355
work_keys_str_mv AT chenjingxian sorafenibfortreatingheadandneckadenocarcinomaofunknownprimarysiteacasereport
AT chengchienshan sorafenibfortreatingheadandneckadenocarcinomaofunknownprimarysiteacasereport
AT chenjie sorafenibfortreatingheadandneckadenocarcinomaofunknownprimarysiteacasereport
AT lvlingling sorafenibfortreatingheadandneckadenocarcinomaofunknownprimarysiteacasereport
AT shenxiaoheng sorafenibfortreatingheadandneckadenocarcinomaofunknownprimarysiteacasereport
AT zhenglan sorafenibfortreatingheadandneckadenocarcinomaofunknownprimarysiteacasereport

Ejemplares similares